These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 17593391

  • 1. Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
    Guérin O, Formento P, Lo Nigro C, Hofman P, Fischel JL, Etienne-Grimaldi MC, Merlano M, Ferrero JM, Milano G.
    J Cancer Res Clin Oncol; 2008 Jan; 134(1):51-7. PubMed ID: 17593391
    [Abstract] [Full Text] [Related]

  • 2. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
    Cumashi A, Tinari N, Rossi C, Lattanzio R, Natoli C, Piantelli M, Iacobelli S.
    Cancer Lett; 2008 Nov 08; 270(2):229-33. PubMed ID: 18586384
    [Abstract] [Full Text] [Related]

  • 3. Combination of sunitinib, cetuximab and irradiation in an orthotopic head and neck cancer model.
    Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi MC, Milano G.
    Ann Oncol; 2009 Oct 08; 20(10):1703-7. PubMed ID: 19542251
    [Abstract] [Full Text] [Related]

  • 4. Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
    Hadaschik BA, Ettinger S, Sowery RD, Zoubeidi A, Andersen RJ, Roberge M, Gleave ME.
    Int J Cancer; 2008 May 15; 122(10):2368-76. PubMed ID: 18240145
    [Abstract] [Full Text] [Related]

  • 5. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
    Ohlmann CH, Markert E, Gerharz M, Pfister D, Dienes HP, Engelmann U, Heidenreich A.
    Urologe A; 2008 Sep 15; 47(9):1218-23. PubMed ID: 18679646
    [Abstract] [Full Text] [Related]

  • 6. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G, Taylor SA, Marrinan CH, Hsieh Y, Bishop WR, Kirschmeier P, Long BJ.
    Int J Cancer; 2009 Dec 01; 125(11):2711-20. PubMed ID: 19530253
    [Abstract] [Full Text] [Related]

  • 7. The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors.
    Jing C, Ning J, Yuanjie N.
    J Cancer Res Clin Oncol; 2012 Dec 01; 138(12):2137-43. PubMed ID: 22868821
    [Abstract] [Full Text] [Related]

  • 8. Functional and pharmacodynamic evaluation of metronomic cyclophosphamide and docetaxel regimen in castration-resistant prostate cancer.
    Cardillo I, Spugnini EP, Galluzzo P, Contestabile M, Dell'Anna ML, Picardo M, Crispi S, Calogero RA, Piccolo MT, Arigoni M, Cantarella D, Boccellino M, Quagliuolo L, Ferretti G, Carlini P, Felici A, Boccardo F, Cognetti F, Baldi A.
    Future Oncol; 2013 Sep 01; 9(9):1375-88. PubMed ID: 23980684
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of cetuximab associated with the taxotere-cisplatin-fluorouracil (TPF) combination on an orthotopic head and neck cancer model.
    Bozec A, Sudaka A, Etienne-Grimaldi MC, Brunstein MC, Fischel JL, Milano G.
    Oral Oncol; 2011 Oct 01; 47(10):940-5. PubMed ID: 21862388
    [Abstract] [Full Text] [Related]

  • 10. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
    Ortholan C, Durivault J, Hannoun-Levi JM, Guyot M, Bourcier C, Ambrosetti D, Safe S, Pagès G.
    Eur J Cancer; 2010 Nov 01; 46(16):3022-36. PubMed ID: 20729074
    [Abstract] [Full Text] [Related]

  • 11. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
    Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE.
    Ann Oncol; 2010 Feb 01; 21(2):319-324. PubMed ID: 19633050
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
    Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S, Swiss Group for Clinical Cancer Research SAKK.
    Clin Cancer Res; 2012 Nov 01; 18(21):6049-57. PubMed ID: 22977195
    [Abstract] [Full Text] [Related]

  • 13. Concurrent and sequential administration of sunitinib malate and docetaxel in human non-small cell lung cancer cells and xenografts.
    Wang D, Jiang Z, Zhang L.
    Med Oncol; 2012 Jun 01; 29(2):600-6. PubMed ID: 21455800
    [Abstract] [Full Text] [Related]

  • 14. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
    Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E, Casanovas O, Mora J, Germà JR, Capellà G, Villanueva A, Viñals F.
    Clin Cancer Res; 2009 May 15; 15(10):3384-95. PubMed ID: 19417025
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.